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Available online 10 September 2016Aneurysm-osteoarthritis syndrome characterized by unpredictable aortic aneurysm formation, is caused by
SMAD3mutations. SMAD3 is part of the SMAD2/3/4 transcription factor, essential for TGF-β-activated transcrip-
tion. Although TGF-β-related genemutations result in aneurysms, the underlying mechanism is unknown. Here,
we examined aneurysm formation and progression in Smad3−/− animals.
Smad3−/− animals developed aortic aneurysms rapidly, resulting in premature death. Aortic wall immunohisto-
chemistry showed no increase in extracellular matrix and collagen accumulation, nor loss of vascular smooth
muscle cells (VSMCs) but instead revealed medial elastin disruption and adventitial inﬂammation. Remarkably,
matrix metalloproteases (MMPs) were not activated in VSMCs, but rather speciﬁcally in inﬂammatory areas.
Although Smad3−/− aortas showed increased nuclear pSmad2 and pErk, indicating TGF-β receptor activation,
downstream TGF-β-activated target genes were not upregulated. Increased pSmad2 and pErk staining in pre-
aneurysmal Smad3−/− aortas implied that aortic damage and TGF-β receptor-activated signaling precede aortic
inﬂammation. Finally, impaired downstream TGF-β activated transcription resulted in increased Smad3−/−
VSMC proliferation.
Smad3 deﬁciency leads to imbalanced activation of downstreamgenes, no activation ofMMPs in VSMCs, and im-
mune responses resulting in rapid aortic wall dilatation and rupture. Our ﬁndings uncover new possibilities for
treatment of SMAD3 patients; instead of targeting TGF-β signaling, immune suppressionmay bemore beneﬁcial.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Aneurysm
Vascular biology
TGF-β signaling pathway
Echocardiography
Mouse model1. Introduction
Aortic aneurysms signiﬁcantly increase the risk of tearing (dissection)
or rupture of the aorta with life-threatening consequences. As for severalome; CTGF, connective tissue
an's syndrome; MMP, matrix
VSMC, vascular smooth muscle
logous.
02, Wytemaweg 80, 3015 CN
. This is an open access article undercardiovascular diseases, male gender, advanced age, and positive family
history are among the main risk factors for developing aneurysms
(Albornoz et al., 2006; Grubb and Kron, 2011).Multiple genes for thoracic
aortic aneurysms have been identiﬁed (Gillis et al., 2013), butmost of the
underlying genetic and molecular interactions are not known. These
genes mainly fall into three categories, based on their function; 1) extra-
cellularmatrix integrity and structure, 2) involvement in TGF-β signaling,
and 3) cytoskeleton maintenance and mobility. Although their functions
are quite different, defects in these genes all lead to aneurysm formation.
The extracellular matrix (ECM) is important for the integrity of
the aortic wall and mutations in ECM genes such as Fibulin-4 and
Fibrillin-1 hence lead to aneurysm formation. Genetic studies inthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the TGF-β pathway as an important hallmark in the pathogenesis
of aneurysm formation, both in mice and humans (Neptune et al.,
2003; Habashi et al., 2006; Hanada et al., 2007; Huang et al., 2010;
Kaijzel et al., 2010; McLaughlin et al., 2006).
Several genes that are involved in cytoskeletal maintenance are mu-
tated in aneurysmal disease. Examples are ACTA2 and MYH11, which
function in the contractile apparatus of the smooth muscle cell, and
mainly cause thoracic aneurysms when mutated (Guo et al., 2007;
Zhu et al., 2006), underscoring the importance of cytoskeleton mainte-
nance and mobility in aneurysmal disease.
The TGF-β pathway plays a relevant role in the etiology of aortic
aneurysms. Twenty years ago, the ﬁrst member of the TGF-β signal-
ing pathway was linked to a genetic vascular disease, after ﬁnding
mutations in the gene coding endoglin (McAllister et al., 1994).
Loss of function mutations in this TGF-β binding protein were de-
scribed to cause hereditary hemorrhagic telangiectasia type I. This
was followed by the discovery of mutations in the receptors
TGFβR1 and TGFβR2 (Loeys et al., 2005; Mizuguchi et al., 2004),
SMAD3 (van de Laar et al., 2011), the ligands TGFβ2 (Lindsay et al.,
2012; Boileau et al., 2012) and TGFβ3 (Bertoli-Avella et al., 2015;
Rienhoff et al., 2013). These mutations lead to a spectrum of system-
ic disorders characterized by aneurysms and other cardiovascular
and skeletal features known as Loeys-Dietz syndrome (LDS).
The SMAD (SMA/MAD homology) proteins are important regula-
tors of the TGF-β signaling pathway and function as signaling trans-
ducers downstream of TGF-β receptors. The SMAD protein family
consists of receptor SMADs (SMAD1–3, SMAD5, SMAD8), the co-ef-
fector SMAD4 and inhibitory SMADs (SMAD6 and SMAD7)
(Massague, 2012; Massague et al., 2005). Activated SMAD2 and
SMAD3 can form heteromeric (pSMAD2/4, pSMAD3/4) complexes
in the nucleus where they form transcription-activating complexes
capable of inducing or repressing the expression of several genes
(Massague et al., 2005; Moustakas and Heldin, 2002) in a cell-type
and SMAD complex-dependent manner.
We recently described a genetic disease characterized by aneu-
rysms, dissections and cardiac abnormalities in combination with
early-onset osteoarthritis (OA) known as aneurysm-osteoarthritis
syndrome (AOS or LDS3; MIM 613795) caused by heterozygous mu-
tations in the SMAD3 gene (van de Laar et al., 2011). Patients carry-
ing heterozygous SMAD3 mutations present with extreme clinical
variability in cardiovascular disease onset and progression (van de
Laar et al., 2012; van der Linde et al., 2012; van der Linde et al.,
2013). The exact molecular mechanisms and contributing factors
underlying this lack of genotype-phenotype correlation remain to
be established, as well as the variable effect that genetic variants of
SMAD3 can have on different tissues. SMAD3 mutations are sug-
gested to lead to upregulation of the TGF-β pathway in the aortic
wall as indicated by nuclear translocated and activated SMAD2
(pSMAD2) (van de Laar et al., 2011). Activated SMAD2 is also seen
uponmutational hits in the TGFβR1/2 receptors, or the TGFβ2 ligand
(Lindsay and Dietz, 2011; Lindsay et al., 2012; Loeys et al., 2005). Be-
cause pSMAD2 is considered to report on activation of the TGFβ
pathway, these ﬁnding are referred to as the TGFβ paradox, as one
would expect that mutations in genes involved the TGFβ pathway
would hamper TGFβ signaling (Akhurst, 2012; Massague, 2012).
However, it is unclear whether pSMAD2 is a functional marker for
the downstream upregulation of the TGFβ pathway. Similarly, muta-
tions in genes involved in build-up and integrity of the ECM lead to
an upregulation of the TGF-β signaling pathway and aneurysm for-
mation. For the ECM related gene mutations it is thought that this
upregulation is due to release of TGF-β ligand from the ECM, caused
by loss of ECM integrity, resulting in ECM remodeling and aortic
stiffness (Gillis et al., 2013). It remains to be seen whether the
same underlying mechanism is at work when comparing ECM- and
TGF-β related gene deﬁciency in aneurysm formation.The clinical heterogeneity in AOS patients makes it difﬁcult to
study SMAD3mutational effects on aneurysm formation. Fortunate-
ly, due to the homogenous genetic background, genetically
engineered mouse models are useful in pinpointing the speciﬁc mo-
lecular mechanism leading to disease. Smad3 knockout animals
present with skeletal abnormalities and osteoarthritis (OA) and as
such, they have been used as a model to study OA (Yang and Cao,
2001; Li et al., 2009). A cardiovascular phenotype in these animals
was overlooked until the recent link of human SMAD3 mutations
and aortic aneurysms was established (Regalado et al., 2011; van
de Laar et al., 2011; Ye et al., 2013). Here we describe the cardiovas-
cular phenotype of the Smad3 knockout mice and reveal the under-
lying mechanism of aneurysm growth caused by a SMAD3
deﬁciency.
2. Materials and Methods
2.1. Experimental Animals
Smad3+/‐ animals were bred into in a C57BL6 background to obtain
Smad3−/− and Smad3+/+ experimental animals (backcross 6). The
numbers of animals, as well as procedures used, are described in the re-
sults section and below, respectively. Animals were housed at the Ani-
mal Resource Centre (Erasmus University Medical Centre), which
operates in compliancewith the “AnimalWelfare Act” of theDutch gov-
ernment, using the “Guide for the Care and Use of Laboratory Animals”
as its standard. As required byDutch law, formal permission to generate
and use genetically modiﬁed animals was obtained from the responsi-
ble local and national authorities. An independent Animal Ethics Com-
mittee of the Erasmus Medical Center (Stichting DEC Consult)
approved these studies (permit number 140–12-05), in accordance
with national and international guidelines.
Litter- and gender matched controls were used for each experiment
when available.
2.2. Echocardiographic Measurements
Ascending aortic diameter wasmeasured in M-mode, aortic root di-
ameterwasmeasured at the site of the sinus of Valsalva in B-mode. Aor-
tic length was measured as the distance between the sinus of Valsalva
and the brachiocephalic trunk. All mice were ventilated and anesthe-
tized with 2.5% isoﬂurane and echocardiography of the ascending
aortawas performed using a Vevo2100 (VisualSonics Inc., Toronto, Can-
ada). Longitudinal echocardiographic measurements of the ascending
aorta were performed on 6, 12, 18 and 26 week old Smad3−/− and
Smad3+/+ mice (n= 18, 8 male and 10 female per genotype).
2.3. Immunohistochemistry
For histological analysis mice were euthanized by CO2-inhala-
tion. After opening thorax and abdomen, mice were ﬁxed by perfu-
sion ﬁxation through the left ventricle, with PBS and formalin.
Organs were weighed and inspected for macroscopic abnormalities.
Organs and tissues were ﬁxed in formalin. Aortas were dehydrated
through the histokinette processor (Microm), and parafﬁn embed-
ded, after which 5-μm sections were prepared. Aortas were stained
with HE for general pathology, Resorcin-Fuchsin (RF; Elastin von
Gieson) for elastin structure, Alcian Blue (AB) to evaluate the extra-
cellular matrix (ECM), and Picrosirius Red (PR) to assess collagen
accumulation.
For immunohistochemical analyses, thoracic aortic sections were
boiled in 100 mM Tris-HCl [pH 9.0] with 10 mM EDTA at 300 W for
20min for antigen exposure, and emerged in 3%H2O2 inmethanol to in-
hibit endogenous peroxidase for pSmad2, α-SMA, pERK, CD31, MMP,
CD3, MAC2 and Ki-67 staining. Slides were ﬁrst blocked in 5% Protifar
in PBS and 0.025% Triton, and incubated with the primary antibodies
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clone 1A4 Dako), pSmad2 (1:100 monoclonal Rabbit anti-pSmad2
(S465|467 (138D4) Cell Signaling), pERK (1:200 Rabbit Polyclonal
anti-pErk (phosphor-p44/42 Mapk (Erk1/2) (Thr202/Tyr204) anti-
body) (#9101) Cell Signaling), MMP-9 (1:50 goat polyclonal anti
MMP-9 (sc-6840) Santa Cruz Biotechnology, Ki-67 (1:200 Rat anti
mouse Ki-67, clone TEC-3, DAKO), MAC-2 (1:500 Rat anti mouse
MAC-2, CL8942AP, Cedarlane), CD31 (1:50 Rabbit pAb to CD31,
ab28364, Abcam), CD3 (1:200 Polyclonal Rabbit anti human CD3,
REF A0452, DAKO). The next day slides were incubated with bio-
tinylated secondary antibodies (1:100 DAKO) and avidin-biotinylat-
ed complex (Vectastain Universal Elite ABC kit Vector Laboratories).
DAB chromogen (DAKO Liquid Dab substrate-chromogen system)
was used as substrate and slides were counterstained with hema-
toxylin. In total 8 Smad3−/− and 8 Smad3+/+ mice were examined
for each staining.
2.4. Molecular Imaging for MMP Activation
We used vascular ﬂuorescent mediated tomography (FMT) im-
aging with near-infrared ﬂuorescent protease activatable probes as
previously described (Kaijzel et al., 2010; Nahrendorf et al., 2011).
As in aortic aneurysms MMP2 and MMP9 are most abundant, the
probe is mostly cleaved by these two proteases. FMT imaging was
performed using an FMT 2500 system (Perkin Elmer, Inc.) at 680/
700 nm excitation and emission wavelengths, 24 h after tail vein in-
jection of 2 nmol per 25 g bodyweight of theMMPsense™ 680 probe,
or at 750/775 nm excitation and emission wavelengths, 6 h after in-
jection of 2 nmol per 25 g bodyweight of the MMPsense™750 FAST
near-infrared ﬂuorescent probe (Perkin Elmer, Inc.), mice were im-
aged in a portable animal imaging cassette between optically trans-
lucent windows. The FMT 2500 quantitative tomography software
was then used to calculate 3D ﬂuorochrome concentration distribu-
tion of the ﬂuorescent signal. After ﬂuorescence imaging, aortas
were harvested and ﬂuorescence was quantiﬁed using the FMT
2500 or Odyssey imaging systems (LI-COR Inc.). Near-infrared im-
ages were obtained in the 680- and 750-nm channels, respectively.
Relative ﬂuorescence intensities were calculated for each
Smad3−/− animals compared to its Smad3+/+ littermate control.
2.5. CT-scans
μCT imaging was performed using a Quantum FX μCT system (90
kV,160 μA,FOV 60mm, 2 min 85mGy scantime) (Perkin Elmer, Inc.).
To visualize the vasculature, blood-pool contrast was administered
via tail vein injection with 150 μl eXIA™160 Iodine based
Radiocontrast (160 mg I/ml) per 25 g bodyweight (Binitio biomedi-
cal). A mouse imaging shuttle device was used to sequentially image
the mice with both the FMT 2500 and Quantum FX, achieving accu-
rate animal positioning to align both the ﬂuorescence and μCTForward primer Reverse
B2M 5′-CTCACACTGAATTCACCCCCA-3′ 5′-GTCTC
Tbp1 5′-TCACTCCTGCCACACCAGCTTC-3′ 5′-TGAC
Ppia 5′-CGCGTCTCCTTCGAGCTGTTTG-3′ 5′-TCCGT
Ppia 5′-GTCTCCTTCGAGCTGTTTGC-3′ 5′-ACCA
Smad7 5′-CAAACCAACTGCAGGCTGTC-3′ 5′-CCCCA
Smad6 5′-GCCACTGGATCTGTCCGATT-3′ 5′-GGTC
Pai-1 5′-TCTTTTTCACATTACAGTGGCCTG-3′ 5′-TTTGG
Fn1 5′-ACGGACATCTGTGGTGTAGC-3′ 5′-CGAG
Timp-1 5′-TCGGACCTGGTCATAAGGGC-3′ 5′-GCTTT
Ltbp1 5′-CCAAACATGGCAGGCAAGTC-3′ 5′-TCCAC
Tgfb1 5′-GTGGACCGCAACAACGCCATCT-3′ 5′-GCAA
Tgfbr1 5′-TCGTCCGCAGCTCCTCATCGT-3′ 5′-ACAC
Tgfbr2 5′-CGCACGTTCCCAAGTCGGATGT-3′ 5′-TCGCTimages. The optical and CT data sets were co-registered in 3 dimen-
sions using the TrueQuant software (Perkin Elmer, Inc.). This multi-
modal approach allows simultaneous monitoring of aneurysm
growth and MMP- activity.2.6. Isolation of SMCs, Characterization, Cell Culture and Proliferation Assay
Vascular SMCs were isolated from the media of the aortic arch of
Smad3−/− and Smad3+/+ mice. The tissue was washed with PBS, cut
into 5 mm pieces with the luminal side on 0.1% gelatin-coated cell
culture dishes and incubated. After 7–10 days, smooth muscle-like
cell outgrowth was observed. SMCs were maintained in DMEM
(Lonza, Leusden, the Netherlands), supplemented with 10% fetal
calf serum (HyClone, Thermo Scientiﬁc, Breda, the Netherlands),
100 U/ml penicillin and 100 μg/ml streptomycin (Sigma-Aldrich,
Zwijndrecht, the Netherlands). For characterization, subconﬂuent
SMCs and HUVECswere grown on coverslips and ﬁxed in 2% parafor-
maldehyde. Cells were permeabilized with PBS/Triton (0.1%) and
blocked with PBS+ (0.5% BSA/0.15% glycine in PBS). Coverslips
were incubated overnight with the primary antibody, anti-Human
Smooth Muscle Actin (1:1000 mouse, clone 1A4 Dako). After wash-
ing, coverslips were incubated with the secondary antibody, alexa
ﬂuor 594 goat anti mouse IgG (1:1000, Life technologies). Coverslips
were mounted in Vectashield with Dapi (Vector Laboratories). For
the proliferation assay, cells were used at passage 5–11. Smad3+/+
and Smad3−/− VSMCs were seeded in triplicate in 6 cm dishes
(5000 cells/well) and allowed to attach. The cells were counted
with the coulter counter every day for a week.2.7. RNA Isolation and Real-time PCR
Thoracic (arch and ascending) aortic tissue from Smad3+/+ and
Smad3−/− mice, snap frozen and stored at −80 °C, was used for
this experiment. RNA was isolated with the RNeasy Fibrous tissue
mini kit (Qiagen) for aortic tissue and the RNeasy mini kit (Qiagen)
for VSMCs. cDNA was made with the iScript cDNA synthesis kit
(Biorad) according to the manufacturer's protocol. Q-PCR was per-
formed with 200 nM forward and reverse primers and iQ™ SYBR®
Green Supermix (biorad) on the CFX384 system (Biorad); denatur-
ation at 95 °C for 3 min, 40 cycles denaturation at 95 °C for 15 s, an-
nealing/extension at 55 °C or 60 °C (as indicated below) for 30 s.
B2M, Tbp1 and Ppia were used as a housekeeping gene. Relative
gene expression levels were determined with the comparative
ΔΔCt method. ΔΔCT = (CT(gene of interest, wildtype) −
CT(reference gene, wildtype)) − (CT(gene of interest, knock-
out) − CT(reference gene, knock-out)), where the fold change is
calculated as 2ΔΔCT.
Primer sequences used for real-time PCR:primer Size (bp) Temp (°C)
GATCCCAGTAGACGGT-3′ 98 55/60
TGCAGCAAATCGCTTGGG-3′ 156 60
AGATGGACCTGCCGC-3′ 186 60
CCCTGGCACATGAATC-3′ 138 55
GGGGCCAGATAATTC-3′ 77 55
GTACACCGCATAGAGG-3′ 188 55
GTGACTCTGTTAATTCATC-3′ 102 55
TCTGAACCAAAACCGC-3′ 91 55
CCATGACTGGGGTGT-3′ 162 55
AGACGTTGATCCCCT-3′ 116 55
TGGGGGTTCGGGCACT-3′ 109 60
TGTAATGCCTTCGCCCCC-3′ 70 60
GGCCATGACATCACTGT-3′ 118 60
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Equal amounts of protein (Lowry protein assay) were separated
by electrophoresis on a 15% SDS-polyacrylamide gel. Proteins were
transferred to a PVDF membrane (Millipore) and blocked with 3%
milk powder (ERK, β-catenin) or 5% BSA (pERK) in PBS containing
0.1% Tween-20. Next, blots were incubated overnight with the primary
antibody (ERK, 1:2000, Rabbit anti p44/42MAPK (Erk1/2), #9102S, Cell2
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TGF-β response in VSMCs was determined using the (CAGA)12 −
MLP− Luciferase promoter reporter construct (Dennler et al., 1998).
This construct contains 12 palindromic repeats of the SMAD3/4 binding
element derived from the PAI-1 promoter and was shown to be highly
speciﬁc and sensitive to TGF-β. The assay was performed as described
previously (Hawinkels et al., 2014). In short, VSMCs were seeded in 1%
gelatin-coated 24-well plates and allowed to attach overnight. Cells, at
subconﬂuent density, were transfected using Lipofectamine 2000
(Invitrogen, Carlsbad, California, USA) according to the manufacturer's
protocol, with the CAGA-luciferase reporter plasmid together with an
SV40 renilla-luciferase plasmid to correct for transfection efﬁciency.
After 6 h medium was changed to DMEM containing 10% FCS|PS and
the cells were incubated for 24 h. Cells were serum starved overnight
after which cells were washed, lysed and luciferase activity was deter-
mined with the dual-glo luciferase assay system according to the
manufacturer's protocol (Promega). Luciferase activity was corrected
for transfection efﬁciency with renilla activity. The relative increase in
luciferase activitywas calculated versus controls. Experimentswere per-
formed with three independent cell lines, in duplicate.
2.10. Statistical Analysis
For the animal experiments described power analysis was per-
formed with α 0.05 and β 0.80, and taking into account a drop-out
rate of 15% due to unforeseen circumstances, which was approved by
the local ethical committee. All experiments described were performed
blinded by using cell line and mouse numbers without genotypes.
Normal distribution of the data was assessed using the Shapiro Wilk
test. The unpaired 2-tailed Student t-test was performed to analyze
the speciﬁc sample groups for signiﬁcant differences. All results are
expressed as mean ± SEM. However, for data with non-normal distri-
bution, log-transformation of the data, followed by the Student t-test,
was performed. For the differences between genotypes in aortic diame-
ter, aortic root diameter, aortic length and aortic distensibility (Fig. 1b, c
and d, S1 Fig. b), TwowayANOVAwas performed in order to account for
gender effect. Survival curve analysis (Fig. 1e) was performed with the
log rank test (with time to death as the outcome). Cell growth curves
(Fig. 7c) were ﬁtted to a nonlinear exponential growth equation after
which slopes of the curve were compared. A p-value b0.05 was consid-
ered to indicate a signiﬁcant difference between groups. In the ﬁgures
p b 0.05 is shown with *, and p b 0.01 with **. All analyses were per-
formed using IBM SPSS Statistics version 21.0 (SPSS Inc., Chicago, IL,
USA) and Graphpad.
3. Results
3.1. Increased Aneurysm Size and Early Death in Smad3−/−Mice
In order examine the dynamics of aneurysm formation and progres-
sion, we set-up a cross-sectional cohort study of Smad3−/−male and fe-
male mice together with their Smad3+/+ littermate controls to perform
echocardiograms at 6, 12, 18 and 26weeks of age. Already at the age of 6
weeks, both Smad3−/−male and female mice showed a signiﬁcant in-
crease in the diameter of the aortic root and ascending aorta compared
to their littermate controls. Male Smad3−/−mice showed a 14% increase
and female Smad3−/−mice showed a 21% increase in aortic root diame-
ter (Fig. 1a, b and c, p b 0.01). In addition, aortic length, measured from
aortic root to the ﬁrst aortic branch, was signiﬁcantly increased in
Smad3−/− mice compared to their wild type littermates; male
Smad3−/− mice showed a 15% increase and female Smad3−/− mice
showed a 26% increase in aortic length (Fig. 1d, p b 0.01). Interestingly,
we observed a correlation between aortic diameter and aortic length in-
crease for Smad3−/− animals, indicating that the aorta is enlarged in
both dimensions (S1 Fig. a). Strikingly, no signiﬁcant difference in aorticdistensibilitywas detected in these animals (S1 Fig. b), demonstratingno
increase in aortic stiffness. Together these data show limited, though sig-
niﬁcant dilatations and elongation of Smad3−/− aortas at 6 weeks of age.
Smad3−/−mice died suddenly between 6 and 30weeks of age with-
out overt symptoms, as opposed to noneof the Smad3+/+mice (Fig. 1e).
This effect was even more pronounced in male Smad3−/− mice, with
65%mortality for themale animals before 3months of age (vs. 22%mor-
tality for female mice), implicating a gender difference in life expectan-
cy. Necropsy analysis showed the occurrence of a severe aneurysm
consisting of a 2 to 5-fold increase in aortic diameter of the ascending
aorta (Fig. 1f). We noticed that the aneurysmatic aortic wall remained
translucent,which could be indicative for absence of large-scale ECM re-
modeling or collagen deposition. HE staining showed altered appear-
ance of smooth muscle cells and apparent changes in aortic wall
structure, such as a thicker aortic wall, including a thicker adventitial
layer (Fig. 1g). Yet, staining of the aorticwall for Alcian Blue or Picosirius
Red showed no differences in proteoglycan and collagen staining,
respectively, between Smad3−/− and Smad3+/+ mice (Fig. 1g), which
indicates that there is no evidence for increased ECMand collagen accu-
mulation. This is also consistentwith the absence of any change in aortic
distensibility. Moreover, this is in sharp contrast to what is seen in the
Fibulin4R/R mouse; in this mouse model, the ECM-involved Fibulin-4
gene is expressed at a 4-fold lower level than wildtype, resulting in
stiff aortas that lose their translucency and show increased ECM accu-
mulation and elastin disorganization in the aortic wall (Hanada et al.,
2007; Moltzer et al., 2011). To better understand the early and sudden
death, we next proceeded with the longitudinal studies at older age to
investigate aneurysm formation over time.3.2. Rapid Aneurysmal Growth in Smad3−/− Mice, Not Restricted to the
Aorta
We performed longitudinal ultrasound studies on both female and
male Smad3−/−mice as well as littermate controls (n = 8 and n = 10
per group, respectively) with baseline measurements starting at the
age of 6 weeks with intervals of 6 weeks. Consistent with aggressive
aneurysmal growth in Smad3−/− animals, there was a drop-out of 4
females and 7 males during the experiment due to sudden death,
which, when possible to determine, all presented with a thoracic aneu-
rysm or a cardiac tamponade (Fig. 2a). Of the surviving Smad3−/−
animals (4 females and 3 males) 50% of the females and 33% of the
males showed a steep increase in aortic diameter in this relative short
time span (Fig. 2b and c). No signiﬁcant increase in aortic diameter
was seen in the matched Smad3+/+ littermate controls in this same
time span (data not shown). These data show that Smad3−/− animals
experience rapid aneurysmal growth, and concurrent early death.
Again, this is in contrast to Fibulin-4R/R animals that are bornwith an an-
eurysm, which shows a slow but progressive growth with age (Te Riet
et al., 2016).
To investigate vascular changes throughout the circulatory system
we performed μCT-scans with an iodine based contrast agent to visual-
ize soft tissues in Smad3−/− and Smad3+/+ mice (n= 3 per genotype).
Remarkably, these μCT scans not only revealed a massive dilatation of
the aorta and increased heart size, but also enlargements in different lo-
cations of the body such as in the jugular vein and the vena cava inferior
(Fig. 2d, white, yellow and blue arrows, respectively). However, dilata-
tion of the jugular vein might also be the consequence of cardiac failure.
These data indicate that in mice, Smad3-related disease is a widespread
and aggressive pathology not restricted to the aorta, similar as previous-
ly observed in human (AOS) patients (Aubart et al., 2014;Martens et al.,
2013; van de Laar et al., 2012; Regalado et al., 2011). The μCT scans of
Smad3−/− animals also showed skeletal abnormalities, such as kypho-
sis, as previously described (Li et al., 2006) and illustrated in our
Supporting video ﬁles, showing the 3D rotation for both a Smad3−/−
and Smad3+/+ mouse (Supporting info ﬁles).
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littermate, illustrating the huge increase in aortic diameter within 12 weeks of time. Green line indicates heart, red line the aorta. d) Representative CT pictures of a Smad3−/− female
(right) and its Smad3+/+ littermate (left), age 4 months, in frontal and side view. Arrows indicate the aortic aneurysm in frontal view (white), enlargement of the jugular vein
(yellow), and vena cava inferior (blue), for the Smad3−/− mouse. Same sites are indicated in the Smad3+/+ animal. Bone abnormalities such as kyphosis are also apparent in the
Smad3−/−mouse.
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Immune Response, pSmad2 and pErk
Histomorphological analysis of ﬁve Smad3−/− aortic walls with an-
eurysms showed changes predominantly in the ascending aorta,
consisting of focal disruption and thinning of the media (Fig. 3a).
Three aortaswith aneurysms showedmarked cystic spaces in themedi-
al wall (Fig. 3a), some of which contained erythrocytes, which was not
seen in Smad3+/+ mice (data not shown). We stained for CD31, an
endothelialmarker, that aligns the endothelialwall of vessels (indicated
with an arrow in Fig. 3a and b), demonstrating that these cystic spaces
actually represented small capillaries in the adventitia of Smad3−/−
aortic walls. Occurrence of these capillaries could indicate (neo)vasculogenesis, possibly as a response to vascular damage (Fig. 3b). In
line with this observation, disruption of the media structure was seen in
conjunction with focal adventitial inﬂammation, ﬁbrosis and granulation
tissue (Fig. 3a). Interestingly, immune inﬁltrations have not been ob-
served in Fibulin-4R/R animals.
Elastin staining clearly showed disruption in the elastin structure of
the aortic wall (Fig. 3c). Strikingly, this differs from Fibulin-4R/R aortic
walls, where accumulation and disorganization of elastin structure was
observed (Hanada et al., 2007; Moltzer et al., 2011). At sites where the
media was still present, SMA staining did not show apparent loss of
VSMCs in Smad3−/− aortic walls (Fig. 3d). To investigate the impact of
Smad3 deﬁciency on the TGF-β signaling pathway, we performed
pSmad2 and pErk immunohistochemical staining on Smad3−/− and
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Fig. 3. Aneurysmal Smad3−/− aortas show an increased immune response, elastin disruption, pSmad2 and pErk activation. a) HE staining of a Smad3−/− aorta with aneurysm showing
disruption of the vascular wall, adventitial inﬂammation, and cystic spaces (example indicated with *). b) CD31 staining shows the endothelial layer (indicated by arrow), but also
alignment of the observed cystic spaces (example indicated with *), showing that these spaces represent vessels in the adventitia. c) Resorcin Fuchsin staining for elastin showed
disrupted elastin structures in the medial layer in aneurysmal Smad3−/− compared to Smad3+/+ aortas. d) Smooth Muscle Actin staining of aneurysmal Smad3−/− aortic walls
showed no apparent loss of VSMCs in the media comparable to Smad3+/+. e) pSmad2 and f) pErk showed increased staining in the aortic wall of aneurysmal Smad3−/− compared to
Smad3+/+ mice. This suggests an increased TGF-β receptor activation. Observations made for n = 8 per group, age 3–4 months old. Bar = 50 μm, m = media, a = adventitia, lu =
lumen. *; cystic space, arrow; endothelial layer.
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non-canonical (pErk) activation of the TGF-β signaling pathway via the
TGF-β receptor. pSmad2 and pErk are activated in the Fibulin-4R/R
mouse model, in other aneurysmal diseases such as Marfan's syndrome
and other TGF-β pathway related aneurysmal diseases (Hanada et al.,
2007; Loeys et al., 2005; Neptune et al., 2003; Renard et al., 2013;
Renard et al., 2010). Both pSmad2 as well as pErk staining (Fig. 3e and
f), showed an increase in the aorta of Smad3−/− animals, indicative of
increased TGF-β receptor activation.
3.4. Inﬂammation-associated MMP Activation in Aneurysmal
Smad3−/−Mice
An important process that is regulated by the TGF-β signaling path-
way is MMP activation. In aneurysmal diseases such as Marfan's syn-
drome, as well as aneurysmal mouse models, including Fibulin-4R/R and
Fibrillin-1 mutant mice, MMP activity is strongly increased (Lemaitre et
al., 2003; Longo et al., 2002; Segura et al., 1998; Kaijzel et al., 2010;
Chung et al., 2007). To examine MMP activation in Smad3−/− aortas,we used molecular imaging with MMPsense near-infrared probes to
monitor MMP activity both in vivo and ex vivo. No signiﬁcant difference
in MMP activation between Smad3−/− (with no or minor aneurysm for-
mation) and Smad3+/+ aortas was observed (Fig. 4a, b and c). Thus,
also suggesting that an increase in MMP may not always correlate with
functional upregulation of the TGF-β signaling pathway. Interestingly,
only 25% of aneurysmatic Smad3−/− aortas did seem to show an increase
in MMP activity (Fig. 4c and d). This is in contrast to Fibulin-4R/R animals
that show increased MMP activity already at a young age in VSMCs of
the aortic wall (Kaijzel et al., 2010). Strikingly, in Smad3−/− animals this
activation was derived from invading immune cells and not from
VSMCs in the medial layer, as evident from immunohistochemical stain-
ing for MMP, CD3 (T-cells) and MAC2 (macrophages) (Fig. 4e). Thus,
since this MMP activation was not seen in the VSMCs, this indicates im-
paired TGF-β signaling downstreamof Smad3 inVSMCs speciﬁcally, lead-
ing to a lack of MMP activation and therefore no ECM remodeling.
Togetherwith theﬁnding thatwedonot see changes in ECMcomposition
(staining Fig. 1g), this can explain the fast expansion and rupture of
Smad3−/− aortas.
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Fig. 4. Inﬂammation-associated MMP activation in aneurysmal Smad3−/− mice. a) Representative in vivo images of male Smad3−/− and Smad3+/+ aortas showing comparable MMP
activation. b) Representative ex vivo images of male Smad3−/− and Smad3+/+ aortas showing similar MMP activation. c) Quantiﬁcation of the ﬂuorescent signal, a measure for MMP
activity, does not show signiﬁcant differences between Smad3−/− and Smad3+/+ aortas. Values for each Smad3−/− aorta are compared to its Smad3+/+ littermate. Both male and
female aortas were used for quantiﬁcation (n = 8 total). The two Smad3−/− aortas with highest relative ﬂuorescence intensity also had an aneurysm. d) Ex vivo images of male
Smad3−/− aortas with an aneurysm occasionally do show increased MMP activation. e) Immunohistochemical staining for MMP9, T cells (CD3) and macrophages (MAC2) in an
aneurysmal Smad3−/− aortic wall, showing that the MMP9 signal is derived from immune cells and not VSMCs (performed for n = 5–7 animals per group, age 3–4 months old).
bar = 100 μm, m=media, a = adventitia, lu = lumen.
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pErk Activation
As it seemed that speciﬁcally Smad3−/− aortas with an aneurysm
showed increased MMP activity, whichmight be derived from immune
cells inﬁltrating the aortic wall, we next wondered which histological
changes may already occur in pre-aneurysmal Smad3−/− animals. HEstaining of aortic walls derived from these Smad3−/− animals showed
morphological changes in VSMC appearance; a more round, less ﬂat-
tened appearance compared to Smad3+/+ aortas (Fig. 5a). Interestingly,
the elastin structure was disrupted at several places in pre-aneurysmal
Smad3−/− aortic walls, whereas SMA staining at these same sites
showed no apparent smoothmuscle cell loss (Fig. 5b and c). Surprising-
ly, pSmad2 and pErk staining were both already increased in the aortas
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Fig. 5. Pre-aneurysmal Smad3−/− animals show elastin disruption, pSmad2 and pErk activation. a) HE staining of pre-aneurysmal Smad3−/− aortas showing altered appearance of VSMCs
in the medial layer. b) Smooth Muscle Actin staining of pre-aneurysmal Smad3−/− aortic walls showed no apparent VSMC loss in the media comparable to Smad3+/+ aortas. c) Resorcin
Fuchsin staining for elastin showed a somewhat disrupted elastin structure in themedial layer of pre-aneurysmal Smad3−/− aortas compared to Smad3+/+. d) pSmad2 staining is already
somewhat increased in the aorticwall of pre-aneurysmal Smad3−/− compared to Smad3+/+mice. e) pErk clearly showed increased staining in the aorticwall of pre-aneurysmal Smad3−/−
compared to Smad3+/+ mice. Observations made for n = 5 per group, age 3–4 months old. Bar = 50 μm, m=media, a = adventitia, lu = lumen.
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the increased pErk staining was much more pronounced. However, at
these sites of increased structural wall damage and increased pErk
staining no apparent immune inﬁltration was observed (Fig. 5a) In
agreement, staining for CD31 and for MAC2 were negative (data not
shown). Together this indicates that both the damage in the aortic
wall and the canonical and non-canonical TGF-β signaling activation,
activated pSmad2, and pErk, precede the structural damage in the me-
dial layers that might trigger the immune response.
3.6. Smad3−/− VSMCs and Aortas Show No Downstream Transcriptional
Activation of TGF-β Signaling
Although Smad3 is not expressed, we ﬁnd an increase in nuclear lo-
cated pSmad2 andpErk activation. As this increased activation normally
affects downstream transcriptional activation, as was shown before in
Fibulin-4R/R aortas (Ramnath et al., 2015),we next decided to investigate
the transcription of genes that should normally be activated in response
to an increase in TGF-β receptor activation. In particular, next to the
aorta itself, we were interested in the transcriptional response in
VSMCs isolated from the aorta, as therewe can exclude the contributionof other cell types such as immune cells or ﬁbroblasts that are clearly
present in the aneurysmal aortas of Smad3−/− animals. We therefore
isolated VSMCs from Smad3−/− and Smad3+/+ aortas, and conﬁrmed
the smooth muscle cell phenotype with SMA staining (Fig. 6a). Next,
we determined the mRNA expression levels of FN-1, PAI-1, Smad7 and
Smad6 (Fig. 6b–e), together with TIMP-1, LTBP-1, TGFβR1, TGFβR2
and TGFβ1 (S2 Fig. a–e) in aortic extracts as well as in aortic VSMCs of
Smad3−/− and Smad3+/+ animals. We found a signiﬁcant decrease in
FN-1, PAI-1 and Smad7 transcription in Smad3−/− aortic extracts as
well as VSMCs compared to Smad3+/+ (Fig. 6b and c). Transcription of
Smad6 and TIMP-1 was decreased in Smad3−/− compared to Smad3+/+
VSMCs and aortas (Fig. 6d, e and S2 Fig. a), and no signiﬁcant change
in LTBP-1 mRNA levels was detected (S2 Fig. b). Interestingly, transcripts
for TGFβR1, TGFβR2 and TGFβ1 were signiﬁcantly decreased in
Smad3−/− VSMCs compared to Smad3+/+, but not in the aortic arch tis-
sue, which could imply that this decrease in TGFβ receptors and TGFβ1
occurs speciﬁcally in VSMCs and not in immune (or other types of) cells
(S2 Fig. c, d and e). These ﬁndings are different from Fibulin-4R/R aortas
where increased TGFβ receptor activation and downstream transcrip-
tional activation of genes such as TGFβ2 and PAI-1 were observed
(Ramnath et al., 2015).
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Downstream Transcriptional Activation
Interestingly, in the Fibulin-4R/R mouse model VSMCs have a higher
downstream TGF-β-activated transcriptional response, which is linked
to their reduced proliferation rate, and which can be rescued by
inhibiting TGF-β (Ramnath et al., 2015). In contrast, during the culturing
of Smad3−/− VSMCs we noticed that they appeared to proliferate faster
than Smad3+/+ VSMCs. We therefore performed Ki67 staining on the
aorta, which speciﬁcally marks proliferative cells, and found an increase
in VSMC proliferation in Smad3−/− aortic walls compared to Smad3+/+
(Fig. 7a) as judged from the positive KI-67 staining. We next set up a
controlled VSMC proliferation experiment, where we started with the
same amount of cells for each genotype and counted the cells each
day for seven days. Indeed, Smad3−/− VSMCs proliferated faster than
Smad3+/+ VSMCs (Fig. 7b). This is different from the Fibulin-4R/R
VSMCs, which proliferate slower than their wild type control cells
(Ramnath et al., 2015). As we observed prominent increased pErkstaining in both pre-aneurysmal as well as aneurysmal Smad3−/− aor-
tas, we next investigated Erk phosphorylation status in both
Smad3−/− as well as Fibulin-4R/R VSMCs. In both Smad3−/− and
Fibulin-4R/R VSMCs pErk was increased compared to their control cell
lines (Fig. 7c), which hence does not explain the increased proliferation
observed in Smad3−/− VSMCs. However, we did observe an impaired
downstream TGF-β transcriptional response in Smad3−/− VSMCs
(Fig. 6). We therefore next decided to measure the transcriptional re-
sponse in isolated Smad3−/− and Fibulin-4R/R VSMCs with a luciferase-
based reporter assay as previously described (Dennler et al., 1998;
Hawinkels et al., 2014; Ramnath et al., 2015). In this assay, a plasmid
containing the SMAD3/4 binding element derived from the PAI-1 pro-
moter is transfected, that is highly speciﬁc and sensitive to TGF-β recep-
tor activation. We measured the transcriptional response without
adding exogenous TGF-β. Although we observed no signiﬁcant change
in transcriptional response for Fibulin-4R/R compared to Fibulin-4+/+
VSMC, Smad3−/− VSMCs showed a signiﬁcantly 5-fold lower response
than Smad3+/+ VSMCs, indicating impaired downstream activation of
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290 I. van der Pluijm et al. / EBioMedicine 12 (2016) 280–294TGF-β responsive genes (Fig. 7d, p b 0.05). These data imply that the
impaired downstream TGF-β induced transcriptional activation affects
cellular fate such as proliferation.
4. Discussion
In humans, SMAD3mutations cause a syndromewith cardiovascular,
craniofacial, cutaneous and skeletal anomalies. Aortic aneurysms and
osteoarthritis characterize this syndrome known as AOS or LDS3. Al-
though an increasing number of SMAD3mutations have recently been
reported (Aubart et al., 2014; Fitzgerald et al., 2014; Hilhorst-Hofstee
et al., 2013; Zhang et al., 1996), the functional effect of these mutations
remains to be explored. The molecular mechanism underlying AOS,
resulting from SMAD3mutations is largely unknown. In this study weinvestigated the vascular phenotype in Smad3 mutant mice and ex-
plored its effects on the TGF-β signaling cascade.
As the functional consequence of heterozygous SMAD3 patient mu-
tations at the protein level is unclear; it might for example lead to a null
or non-functional protein (e.g. not able to bind SMAD2), we decided to
study the effect of Smad3 deletion in Smad3−/−mice to better under-
stand its role in aneurysm formation. In Smad3−/− mice, Smad3 deﬁ-
ciency leads to aortic aneurysms, which mainly affect the aortic root
and ascending aorta, but also extends to othermajor arteries. Aneurysm
formation is highly dependent on the age of the animals, as has been
observed in AOS patients with SMAD3 mutations, which display an
age-dependent penetrance. As shown here, male Smad3−/− animals
suffered a more severe aortic phenotype (both dilatation and elonga-
tion) and consequently, died earlier than female Smad3−/− animals.
291I. van der Pluijm et al. / EBioMedicine 12 (2016) 280–294The resulting phenotype due to Smad3 deﬁciency inmice is very similar
to the vascular phenotype described in patients with SMAD3mutations
offering an excellent opportunity for disease modeling. Despite the ho-
mogeneous genetic background aneurysms still present irregularly in
the Smad3−/−mice, which suggests that other external factors, like for
example blood pressure and subtle intrinsic variations in transcriptional
activation can also determine the variability in the resulting phenotype.
Strikingly, histology of the aortic wall shows that, unlike other
models for aneurysmal disease, there is no increase in ECM accumula-
tion, nor excessive collagen staining, or loss of vascular smooth muscle
cells. However, we observe increased aortic pSmad2 and pERK activa-
tion. Moreover, this activation is already apparent before Smad3−/− an-
imals present with aneurysms, showing that this activation precedesSmad3 deficiency
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sion of pSMAD2, pERK1/2 and CTGF (Loeys et al., 2005; van de Laar et al.,
2011; Lindsay et al., 2012). This phenomenon is known as the TGF-β par-
adox (for comprehensive review see (Massague, 2012)). We therefore
examined TGF-β receptor activation in the aortic wall of Smad3−/− ani-
mals by investigating pSmad2 expression. We observed that while lack-
ing Smad3, Smad2 can still be phosphorylated and transported to the
nucleus. Thus, lack of Smad3 might alter downstream transcriptional ac-
tivation in the nucleus (also see Fig. 8). This lack of Smad3might also shift
TGF-β activated signaling via Smad2, which has similar but not overlap-
ping functions (Moustakas and Heldin, 2002; Zhang et al., 1996), also
resulting in an altered transcriptional response. We reasoned that these
changes lead to reduction in the downstream transcription of genes
such as ECM components and MMPs. Indeed, we demonstrate here that
transcriptional activation ofmultiple genes downstreamof the TGF-β sig-
naling cascade is absent. Again, this is in contrast to what was previously
found for Fibulin-4R/R aortas and VSMCs where downstream TGF-β-in-
duced transcription was activated (Ramnath et al., 2015). Moreover, we
found that the increased proliferation of Smad3−/− VSMCs is not due to
increased pErk, but rather due to the lack of downstream TGF-β induced
transcriptional activation. Moreover, it shows that Smad3 normally plays
a role in TGF-βmediated growth inhibition.
We also examined Smad7 as an important regulator of the TGF-β
signaling pathway as it inhibits phosphorylation of Smad2 by the TGF-
β receptors, thereby acting as a negative feedback loop in this pathway
to prevent deregulation. Without Smad7, TGF-β receptor activation
cannot be inhibited -explaining for example increased pSmad2- but
downstream transcriptional activation remains impaired since Smad3
is lacking (See Fig. 8, left panel for a schematic overview). In agreement,
we found no upregulation of Smad7 in Smad3−/− aortas, or of other
downstream genes such as PAI-1.
When we now compare the ﬁndings between Smad3−/− and
Fibulin-4R/R animals, although in both mouse models aneurysms are
formed, the underlying cause and phenotypical consequences are
quite different (Fig. 8). In Fibulin-4R/R aortas it is thought that TGF-β is
released from the matrix, resulting in activation of TGF-β signaling
pathway, which eventually also results in activated downstream tran-
scription. However, in Smad3−/− animals, although there can be activa-
tion of TGF-β receptors, as also shown by increased pSmad2 signal,
transcriptional activation downstream of Smad3 is impaired. One im-
portant downstream gene that is normally transcribed is SMAD7,
which is a potent inhibitor of the TGF-β signaling pathway. We ﬁnd de-
creased Smad7 transcripts, which might explain the continued activa-
tion of the TGF-β receptor. Furthermore, this altered signaling and
transcriptional pattern might also lead to an altered ‘appearance’ of
the VSMCs for the immune system, thereby attracting immune cells.
In accord, Smad3−/− animals suffered from so-called ‘sterile’ infections
in the aortic wall, as derived from the HE stained sections showing inﬁl-
trations of immune cells. As these inﬁltrations were only observed after
dilatation of the aorta became apparent, this might suggest that this im-
mune reaction is triggered after the aneurysm is formed. Indeed, Ye et
al. showed that administration of anti-GM-CSF antibody to Smad3−/−
mice reduced inﬂammation and also diminished aorta dilation (Ye et
al., 2013). This would also be in agreement with the fact that we only
observed MMP activity in aortas with an aneurysm that could be traced
back to the immune cells adjacent to the adventitia of the aortic wall.
Moreover, the fact that here the MMP activation is derived from im-
mune cells rather than from VSMCs, and is only present at late stages
of aneurysm formation, after the immune inﬁltrates are present,
would argue that MMP activity is a good marker for aneurysm forma-
tion caused by ECM deﬁciencies, but not for those due to SMAD3muta-
tions. The longitudinal echocardiograms showed dilatations with a
rapid increase of the aneurysm within a very short period of time. It
could be that the increased upstream TGF-β receptor activation, togeth-
erwith the lack of collagen and ECMaccumulation results in dilatations;
the structural integrity fails progressively. This, together with a possiblyaltered appearance of the VSMC both in structure as well as transcrip-
tional proﬁle, could attract immune cells, which start cleaning up the
detected ‘vascular damage’ at the expense of macrophage-induced de-
terioration of the already fragile aortic wall. This would then explain
the rapid and aggressive aneurysmal growth.
Most genetic studies have been focusing on delineating the clinical
phenotype associated with SMAD3 mutations (Hilhorst-Hofstee et al.,
2013; Aubart et al., 2014; Fitzgerald et al., 2014; Wischmeijer et al.,
2013; van der Linde et al., 2012). Despite the increasing number of
reportedmutations, functional studies indicating the pathological effect
of these mutations are lacking. Existing experimental data and molecu-
lar predictions suggest that SMAD3mutations are mainly loss of func-
tion (van de Laar et al., 2011; Aubart et al., 2014). Many reported
mutations lead to frame shifts, deletions and likely nonsense mediated
decay. Others are perturbing the heterodimer formation SMAD3/4 or
leading to nonfunctional complexes. Yet, a dominant-negative effect of
some mutations cannot be excluded.
The ﬁnding of an aortic phenotype in a mouse model with a com-
plete Smad3 deﬁciency very similar to the human disease supports the
idea that also lack of functional SMAD3 could cause the human clinical
phenotype. A similar scenario has been described for the TGF-β2
mouse model (Boileau et al., 2012). Moreover, in aneurysmal diseases
such asMarfan's syndrome (MFS), the efﬁcacy of interventions that tar-
get the TGF-β signaling pathway is being explored. So far the effects on
delay of aneurysmal growth are quite promising (Neptune et al., 2003;
Ng et al., 2004; Habashi et al., 2006; Cohn et al., 2007). However, similar
intervention strategies might not be beneﬁcial in case of a Smad3 deﬁ-
ciency. Since downstream transcriptional activation is hampered in
the absence of Smad3, inhibition of components in the TGF-β signaling
pathwaymight in this caseworsen the outcome as even less ECMwould
be generated, and alternative ‘escape’ pathways would be blocked.
In conclusion, Smad3 deﬁciency leads to aortic aneurysms and sudden
death in the Smad3 knockout animalmodel. This phenotype is inﬂuenced
by age and gender of the animals. Although Smad3 is absent,we observed
increased nuclear translocation of pSmad2, and upregulated pERK signal-
ing, inferring increased upstream TGF-β receptor activation. However,
the downstream TGF-β-activated transcriptional response seemed im-
paired as derived from the absence of MMP activation and lack of amor-
phous ECM accumulation in Smad3−/−mouse aortas. Together our data
stress the importance of identifying the molecular mechanism of aneu-
rysmal disease, as the outcome, and therefore treatment options, can dif-
fer dramatically. At the same time, the Smad3−/−mouse proves to be an
ideal model to start testing these different interventional options on.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.09.006.
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